tbuckley/cabot-search huggingface dataset:
Concept, Feasibility and Results of the Randomized Comparison of Imatinib Combination Therapies for Chronic Myeloid Leukemia: The German CML-Study IV.
Authors: Ute Berger, Andreas Hochhaus, Markus Pfirrmann, Claudia Schoch, Andreas Reiter, Gerhard Ehninger, Thomas Fischer, Alois Gratwohl, Joerg Hasford, Hermann Heimpel, Dieter K. Hossfeld, Hans-J. Kolb, Stefan Krause, Christoph Nerl, Hans Pralle, Andreas Tobler, Ruediger Hehlmann
Journal: Blood (2005)
Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.
Authors: Michele Milella, Sabina Chiaretti, Maria R. Ricciardi, Simona Tavolaro, Ludovica Ciuffreda, Barbara Benassi, Alfonso Bellacosa, Gianfranco Peluso, Paola Bergamo, James A. McCubrey, Francesco Cognetti, Gabriella Zupi, Robert Foà, Agostino Tafuri
Journal: Blood (2007)
Prophylaxis of Cytomegalovirus (CMV) Infection and Disease after Unrelated-Donor Umbilical Cord-Blood Transplantation (UCBT) with Intravenous Ganciclovir or Oral Valganciclovir.
Authors: Guillermo Sanz, Susana Cantero, Ignacio Lorenzo, Barbara Benlloch, Luis Benlloch, Maria Narvaez, Dolores Planelles, Luis Larrea, Isidro Jarque, Carmen Jimenez, Maria L. Marty, Miguel Gobernado, Miguel A. Sanz
Journal: Blood (2005)
PWE-027 Feeding Tregs for Therapeutic In Vitro Expansion – Retinoic Acid not SCFA Provides The Best Diet
Authors: R Goldberg, C Scotta, J Canavan, P Irving, N Powell, J Sanderson, G Lombardi, G Lord
Journal: Gut (2016)

<h3>Introduction</h3> We have shown that Tregs expanded with rapamycin from FACS-sorted Crohn’s Disease (CD) peripheral blood (PB) CD4+CD25hiCD127loCD45RA+ precursors, yield an epigenetically stable FOXP3+ cell population that is resistant to pro-inflammatory cytokine expression.<sup>1</sup> We will utilise this for a first in man clinical trial of Treg therapy for Crohn’s disease. We wished to optimise the expression of gut homing molecules on these cells as Tregs are required at the site of action for optimal suppressive ability. <h3>Methods</h3> Tregs were isolated from peripheral blood of CD patients and healthy controls. Retinoic acid (RA) and Rapamycin supplementation was tested in standard culture conditions as well as the addition of short chain fatty acids (SCFA). The effect of SCFA was assessed on ex-vivo expanded Tregs from CD4+CD25hiCD127loCD45RA+ precursors and induced Tregs (iTreg) from naïve T cell precursors. The expression of gut homing molecules integrin b7 and GPR15 was assessed by flow cytometry. Suppressive ability was tested in vitro using autologous effector T cells (Teff). Parametric and non-parametric data were calculated as the mean±s.d. and median (interquartile range, IQR) respectively. For comparison of parametric and non-parametric data, t- test, one- or two-way ANOVA. <h3>Results</h3> In comparison to Rapamycin treated cells, the addition of RA significantly increased the expression of integrin beta 7 (38.7%±11.78% Rapamycin alone vs 72.26%±8.98% Rapamycin + RA p = 0.04, N = 7). RA treatment also significantly increased GPR15 expression. Cells treated with RA maintained their superior suppressive ability compared to Rapamycin treated Tregs (95.8%±3.5% vs 91.15%±10.1% p=ns; at Treg:Teff 1:1 ratio). SCFA treatment led to diminished cell viability and did not induce the expression of colonic homing molecule GPR15 in CD4+CD25hiCD127loCD45RA+ Tregs (74.4%±13.2% Rapamycin and RA treated culture vs 43.4%±17% with the addition of SCFA). <h3>Conclusion</h3> Contrary to existing evidence in mouse, SCFA did not increase the proportion of CD4+FOXP3+ Tregs in human iTreg cultures. In conclusion, the addition of Retinoic acid not SCFA provides the optimal conditions for ex-vivo Treg expansion for cell based therapy of Crohn’s disease. <h3>Reference</h3> 1 Canavan JB, Scotta C, Vossenkamper A, Goldberg R, Elder MJ, Shoval I, <i>et al</i>. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn’s disease. <i>Gut.</i> 2015. <h3>Disclosure of Interest</h3> None Declared
In Vitro and in Vivo Targeting of Chronic Lymphocytic Leukemia Using CX-4945, a Clinical-Stage CK2-Specific Inhibitor.
Authors: Leila R. Martins, Paulo Lúcio, Alice Melao, Bruno A. Cardoso, Ryan Stansfield, Denis Drygin, Maria Gomes Silva, Joao T. Barata
Journal: Blood (2012)
Pertuzumab in metastatic breast cancer (MBT) HER-2 +: Experience of the Department of Medical Oncology, Ospedale Oncologico Regionale “A. Businco”, Cagliari, Italy
Authors: E. Valle, D. Farci, B. Fiori, E. Defraia, G. Gutmann, G. Liciardi, M. Pintus, Y. Urracci, F.M. Tanca
Journal: Annals of Oncology (2015)
Ultrathin Injectable Sensors: Ultrathin Injectable Sensors of Temperature, Thermal Conductivity, and Heat Capacity for Cardiac Ablation Monitoring (Adv. Healthcare Mater. 3/2016)
Authors: Ahyeon Koh, Sarah R. Gutbrod, Jason D. Meyers, Chaofeng Lu, Richard Chad Webb, Gunchul Shin, Yuhang Li, Seung-Kyun Kang, Yonggang Huang, Igor R. Efimov, John A. Rogers
Journal: Advanced Healthcare Materials (2016)

On page 373, I. R. Efimov, J. A. Rogers, and co-workers report classes of ultrathin injectable sensors for spatiotemporal determination of temperature, thermal conductivity, and heat capacity of biological tissues. These flexible devices provide unique capabilities in monitoring of depth-dependent changes in the properties of myocardial tissue that result from cardiac ablation therapy. The materials and mechanical designs provide minimally invasive, biocompatible operation.
Reciprocal Interaction between Megakaryocytes and Myeloma Cells Results in Increased Survival and Proliferation of Myeloma Cells.
Authors: Shmuel Yaccoby, Rinku Saha, Ewa Kozlowska, Yun Ge, Wen Ling, Michele Cottler-Fox, Bart Barlogie, Guido Tricot
Journal: Blood (2005)
SP0161 Latest Advances in The Treatment and Management of Systemic Sclerosis
Authors: U. Müller-Ladner
Journal: Annals of the Rheumatic Diseases (2016)

Based on the 2009 EULAR recommendations for the treatment of systemic sclerosis (SSc), a complete set with attention to new therapeutic approaches was analysed and verified for clinical use. This update of the previous treatment recommendations was performed according to EULAR standard operating procedures. The task force consisted of 32 SSc clinical experts from Europe and USA, two patients nominated by the pan-European patient association for SSc (FESCA), a clinical epidemiologist and 2 research fellows. All centers from the EULAR Scleroderma Trials and Research (EUSTAR) group were invited to submit and select clinical questions concerning SSc treatment using a Delphi approach. Accordingly, 46 clinical questions addressing 26 different interventions were selected for systematic literature review. The new recommendations were based on the available evidence and developed in a consensus meeting with clinical experts and patients. The procedure resulted in sixteen recommendations being developed (instead of 14 in 2009) that address treatment of several SSc-related organ complications: Raynaud9s phenomenon (RP), digital ulcers (DUs), pulmonary arterial hypertension (PAH), skin and lung disease, scleroderma renal crisis, and gastrointestinal involvement. Compared with the 2009 recommendations, the 2015 recommendations include phosphodiesterase type 5 (PDE-5) inhibitors for the treatment of SSc-related RP and DUs, riociguat, new aspects for endothelin receptor antagonists, prostacyclin analogues, and PDE-5 inhibitors for SSc-related PAH. New recommendations regarding the use of fluoxetine for SSc-related RP and haematopoietic stem cell transplantation for selected patients with rapidly progressing SSc were also added. In addition, several comments regarding other treatments addressed in clinical questions and suggestions for the SSc research agenda were formulated. Taken together, these updated data- and consensus-derived recommendations will help rheumatologists to manage patients with SSc in an evidence-based way. These recommendations also give directions for future clinical research in SSc and add to the emerging novel therapies for the different aspects of SSc. <h3>Disclosure of Interest</h3> U. Müller-Ladner Grant/research support from: EULAR, EUSTAR, WSF
How group members contribute to group performance: Evidence from agent-based simulations
Authors: Igor Douven
Journal: Behavioral and Brain Sciences (2016)

The authors argue that group performance depends on the degree to which group members identify with the group as well as on their degree of differentiation. In this commentary, I discuss results from agent-based simulations, suggesting that group performance depends, at least in part, on features orthogonal to agents' caring about group performance or about how they are perceived by other group members.
Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma – Final Results of a Multicenter Prospective Randomised Phase II Study.
Authors: Mathias Witzens-Harig, Axel Benner, Michael Rieger, Fabienne McClanahan, Manfred Hensel, Kai Neben, Peter Dreger, Eva Lengfelder, Ingo Schmidt-Wolf, Krämer Alwin, Anthony D. Ho
Journal: Blood (2009)
B-CLL Antibodies Comprised of Stereotypic VH1-69, D3-16, and JH3 Rearrangements Immunoprecipitate Cellular Protein(s).
Authors: Charles C. Chu, Xiao Bo Wang, Katerina Hatzi, Rosa Catera, Eric Meffre, Maxime Herve, Steven L. Allen, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2006)
Phase II Trial of Rituximab in the Treatment of Inhibitors in Congenital Hemophilia A: Results of the RICH Study
Authors: Cindy A. Leissinger, Rebecca Kruse-Jarres, Suzanne Granger, Barbara A Konkle, Margaret V. Ragni, Janna M. Journeycake, Ellis J. Neufeld, Cassandra Josephson, Carolyn M. Bennett, Leonard A. Valentino, Nigel S. Key, Leslie Raffini, Marcela Torres, Joan Cox Gill, Susan Assmann
Journal: Blood (2011)
FRI0377 Classification Criteria for Giant Cell Arteritis: Data from Giacta Informing The Need for Revision:
Authors: K. Tuckwell, N. Collinson, M. Klearman, S. Dimonaco, J.H. Stone
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Classification criteria are often used to standardize the enrollment of patients (pts) in clinical studies. American College of Rheumatology (ACR) classification criteria for giant cell arteritis (GCA)<sup>1</sup> are &gt;25 years old. Advances in diagnosis and clinical understanding of GCA make their relevance to current studies questionable. <h3>Objectives</h3> To compare inclusion criteria for the GiACTA (tocilizumab for GCA) study<sup>2</sup> with 1990 ACR GCA classification criteria. <h3>Methods</h3> Pts were enrolled into GiACTA according to study inclusion criteria and were evaluated as to whether they met the 1990 ACR classification criteria (Table). Data are from a live database. <h3>Results</h3> Of the 251 pts enrolled into GiACTA, 198 (79%) pts met the 1990 ACR classification criteria. The 53 pts who did not fulfill ACR criteria were eligible for GiACTA based on cross-sectional imaging studies and/or polymyalgia rheumatica (PMR) symptoms. In total, 156 (62%) pts had positive temporal artery biopsies (TAB); of these, 24 also had positive imaging findings. The remaining 95 (38%) pts had no TAB or negative TAB; diagnosis of GCA was confirmed by positive findings from large-vessel imaging studies. Positron emission tomography (PET), often coupled with computed tomography (CT), was important in diagnosis. Positive PET/CT findings contributed to GCA diagnosis in 97 (39%) GiACTA pts. CT angiography and magnetic resonance angiography contributed to diagnosis in 14 (6%) and 8 (3%) pts, respectively. New-onset headache, the only GCA symptom in the ACR criteria, was absent in 33% of GiACTA pts. However, other symptoms that often accompany GCA (PMR, scalp tenderness, jaw claudication, ischemia-related vision loss) were present in 62%, 36%, 34%, and 10% of pts, respectively. <h3>Conclusions</h3> The 1990 ACR classification criteria for GCA require updating. Cross-sectional imaging, particularly PET/CT, now plays a major role in establishing the diagnosis of GCA. Symptoms in addition to headache merit consideration as part of revised classification criteria. <h3>References</h3> Arthritis Rheum 1990;33:1122. Int J Rheumatol 2013;2013:912562. doi: 10.1155/2013/912562. <h3>Disclosure of Interest</h3> K. Tuckwell Shareholder of: Roche, Employee of: Roche Products Ltd., N. Collinson Shareholder of: Roche, Employee of: Roche Products Ltd., M. Klearman Shareholder of: Roche, Employee of: Genentech, S. Dimonaco Employee of: Roche Products Ltd., J. Stone Grant/research support from: Roche, Genentech, Consultant for: Roche, Genentech
Clinical Outcome of Patients with Myelophthisic Anemia Arising From Advanced Gastric Cancer.
Authors: Ji Yeon Kwon, Han Jo Kim, Kyoung Ha Kim, Se-Hyung Kim, Sang-Cheol Lee, Hyun Jung Kim, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu-Taek Lee, Sung Kyu Park, Jong-Ho Won, Dae-Sik Hong, Hee-Sook Park
Journal: Blood (2009)
Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)
Authors: Srdan Verstovsek, Ruben A. Mesa, Susanne Kloeker Rhoades, Jennifer L K Giles, Celine Pitou, Emma Jones, Richard A Walgren, Josef T. Prchal
Journal: Blood (2011)
Comparison of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Mustafa Merter, Erden Atilla, Ugur Sahin, Sinem Civriz Bozdag, Meltem Kurt Yuksel, Pervin Topcuoglu, Onder Arslan, Muhit Ozcan, Taner Demirer, Gunhan Gurman, Osman Ilhan, Hamdi Akan, Meral Beksac, Selami Kocak Toprak
Journal: Blood (2015)
1 year weight losses in the Tianjin Gestational Diabetes Mellitus Prevention Program: a randomised trial
Authors: Huikun Liu, Leishen Wang, Shuang Zhang, Junhong Leng, Nan Li, Weiqin Li, Huiguang Tian, Lu Qi, Jaakko Tuomilehto, Xilin Yang, Zhijie Yu, Gang Hu
Journal: The Lancet Diabetes & Endocrinology (2016)
Chromoendoscopy for Surveillance in Ulcerative Colitis and Crohn’s Disease: A Systematic Review of Randomized Trials
Authors: Andrea Iannone, Marinella Ruospo, Germaine Wong, Mariabeatrice Principi, Michele Barone, Giovanni F.M. Strippoli, Alfredo Di Leo
Journal: Clinical Gastroenterology and Hepatology (2016)
Healthcare Services Needs and Co-Morbidity Assessment Among Adolescents and Young Adults with Cancer: the AYA Hope Study
Authors: Pinki K. Prasad, Ian Landry, Theresa H. M. Keegan, Lynne Harlan, Helen Parsons, Charles F Lynch, Ashley Wilder - Smith, Ann S. Hamilton, Xiao-Cheng Wu
Journal: Blood (2014)
The Story of Scabies. Volume I: The Prevalence (Civil and Military), Prevention and Treatment of Scabies, and the Biology of Acarus Scabiei, from the Earliest Times to the Beginning of World War II
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Peptide hLF1-11 as Broad Spectrum Antmicrobial Prophylaxis in HSCT Patients.
Authors: Marty Wulferink, Carlo P. Brouwer, Astrid M.C. Sluiter-van Dijk, Nicole N.A. Blijlevens, J. Peter Donnelly, Markwin P. Velders
Journal: Blood (2005)
BMET-22DIFFERENT SPATIAL DISTRIBUTION OF BRAIN METASTASIS FROM LUNG CANCER DEFINED BY EGFR MUTATION STATUS
Authors: Koji Takano, Manabu Kinoshita, Masatoshi Takagaki, Mio Sakai, Kazumi Nishino, Junji Uchida, Toru Kumagai, Jiro Okami, Fumio Imamura, Masahiko Higashiyama, Naoya Hashimoto, Toshiki Yoshimine
Journal: Neuro-Oncology (2015)

PURPOSE: To test this hypothesis that different genetic backgrounds of lung cancers could affect spatial distribution of brain metastasis. EXPERIMENTAL DESIGN: CT or MR images of 200 patients with a total of 1033 treatment naive brain metastases from lung cancer were retrospectively collected. All images were deformed and standardized to MNI 152 standard human brain MRI. Locations of the lesions, depths of the lesions from brain surface, and sizes of the lesions after image standardization were analyzed and compared between histological subtypes of the primary lesion as well as EGRF mutation status. RESULTS: The posterior fossa, the anatomic watershed areas and the grey-white matter junction were confirmed to be predilection areas of lung cancer brain metastasis and brain metastasis with L858R occurred more often in caudate, cerebellum and temporal lobe than those with Ex19Del. Among adenocarcinoma lung cancer patients, depths of the lesions from brain surface were 15.7 ± 9.1mm for Ex19Del, 12.6 ± 8.5mm for L858R and 16.1 ± 8.5mm for WT. The lesions with L858R were located statistically significantly closer to the brain surface than the lesions with Ex19Del or WT (p = 0.0032 and p < 0.0001, respectively). On the other hand, there was no statistically significant difference in tumor size among different EGFR mutation status (p = 0.086). Furthermore, brain metastases of adenocarcinoma lung cancer patients with history of chemotherapy treatment were located statistically significantly deeper from brain surface (p = 0.0002). History of molecular targeted therapy did not have any effect on the depth of the lesion. CONCLUSIONS: This analysis is the first to reveal the relationship between tumor's molecular biological characteristics, namely EGFR mutation status and spatial distribution of brain metastases of lung cancer.
A Notch Mutational Hierarchy Among Human T-ALL Leukemia Stem Cells.
Authors: Wenxue Ma, Alejandro Gutierrez, Daniel Goff, Angela Court-Recart, Alice Shih, Qingfei Jiang, Anil Sadarangani, Christina Wu, Christina Jamieson, Mitchell Diccianni, Ping Wei, Todd Van Arsdale, Thomas Look, Catriona Jamieson
Journal: Blood (2010)
Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study
Authors: Paola Guglielmelli, Annalisa Pacilli, Giada Rotunno, Alessandro Pancrazzi, Tiziana Fanelli, Lisa Pieri, Raimonda Fjerza, Chiara Paoli, Lucia Merli, Marker Mahtab, Ana Rodriguez, Alessandro M. Vannucchi
Journal: Blood (2015)
An miRNA–DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia
Authors: Françoise Solly, Catherine Koering, Aminetou Mint Mohamed, Delphine Maucort-Boulch, Guillaume Robert, Patrick Auberger, Pascale Flandrin-Gresta, Lionel Adès, Pierre Fenaux, Olivier Kosmider, Emmanuelle Tavernier-Tardy, Jérôme Cornillon, Denis Guyotat, Lydia Campos, Franck Mortreux, Eric Wattel
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Azacitidine inhibits DNA methyltransferases, including DNMT1, and is currently the standard of care for patients with higher-risk myelodysplastic syndrome (HRMDS) or low blast count acute myeloid leukemia (AML). Experimental Design: The expression of 754 miRNAs was compared in azacitidine-resistant and azacitidine-sensitive myelodysplastic syndrome cells. We investigated the role of differentially expressed miRNAs on DNMT1 expression and azacitidine resistance in vitro. We next evaluated anti-DNMT1 miRNA expression in pretreatment bone marrow samples derived from 75 patients treated with azacitidine for HRMDS or AML. Results: Seven miRNAs, including 5 that in silico targeted the DNMT1 3′ UTR, were repressed in azacitidine-resistant cells in which DNMT1 protein levels were significantly higher. Ectopic anti-DNMT1 miRNA expression decreased DNMT1 expression and increased azacitidine sensitivity, whereas specific inhibition of endogenous anti-DNMT1 miRNAs increased DNMT1 expression and triggered azacitidine resistance. In patients treated with azacitidine, decreased expression of anti-DNMT1 miRNAs was associated with poor outcome. miR-126* had the strongest prognostic impact. Patients with miR-126*low myelodysplastic syndrome had significantly lower response rates (P = 0.04) and higher relapse rates (P = 0.03), as well as shorter progression-free (PFS; P = 0.004) and overall survival (OS; P = 0.004). Multivariate analysis showed that age, miR-126* expression, and revised International Prognostic Scoring System risk independently predicted PFS and OS. In 15 patient samples collected over time, decreased miRNA expression levels were associated with secondary resistance. Conclusions: A decreased expression of anti-DNMT1 miRNAs might account for azacitidine resistance in HRMDS and AML, and measuring miRNA expression before and during treatment might help predict primary or secondary azacitidine resistance. Clin Cancer Res; 23(12); 3025–34. ©2016 AACR.
Mental Health and Social Networks After Disaster
Authors: Richard A. Bryant, H. Colin Gallagher, Lisa Gibbs, Philippa Pattison, Colin MacDougall, Louise Harms, Karen Block, Elyse Baker, Vikki Sinnott, Greg Ireton, John Richardson, David Forbes, Dean Lusher
Journal: American Journal of Psychiatry (2016)

Although disasters are a major cause of mental health problems and typically affect large numbers of people and communities, little is known about how social structures affect mental health after a disaster. The authors assessed the extent to which mental health outcomes after disaster are associated with social network structures.In a community-based cohort study of survivors of a major bushfire disaster, participants (N=558) were assessed for probable posttraumatic stress disorder (PTSD) and probable depression. Social networks were assessed by asking participants to nominate people with whom they felt personally close. These nominations were used to construct a social network map that showed each participant's ties to other participants they nominated and also to other participants who nominated them. This map was then analyzed for prevailing patterns of mental health outcomes.Depression risk was higher for participants who reported fewer social connections, were connected to other depressed people, or were connected to people who had left their community. PTSD risk was higher if fewer people reported being connected with the participant, if those who felt close to the participant had higher levels of property loss, or if the participant was linked to others who were themselves not interconnected. Interestingly, being connected to other people who in turn were reciprocally close to each other was associated with a lower risk of PTSD.These findings provide the first evidence of disorder-specific patterns in relation to one's social connections after disaster. Depression appears to co-occur in linked individuals, whereas PTSD risk is increased with social fragmentation. These patterns underscore the need to adopt a sociocentric perspective of postdisaster mental health in order to better understand the potential for societal interventions in the wake of disaster.
Automated quantification of three-dimensional organization of fiber-like structures in biological tissues
Authors: Zhiyi Liu, Dimitra Pouli, Disha Sood, Aswin Sundarakrishnan, Carrie K. Hui Mingalone, Lisa M. Arendt, Carlo Alonzo, Kyle P. Quinn, Charlotte Kuperwasser, Li Zeng, Thomas Schnelldorfer, David L. Kaplan, Irene Georgakoudi
Journal: Biomaterials (2016)